PDS Biotechnology Corp
PDSB
NASDAQ
Biotechnology
$0.23
USD
0.00 (-1.11%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $13.04M
Volume 1.7M
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-33.36M
TTM
+6.0%
YoY
Operating Cash Flow
$-23.09M
TTM
+32.3%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 3.3 | 3.4 | 3.6 | 2.3 | 3.1 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 9.1 | 7.6 | 8.1 | 6.7 | 6.5 |
Operating Income | -9.1 | -7.6 | -8.1 | -6.7 | -6.5 |
EBITDA | -9.1 | -7.6 | -8.1 | -6.7 | -6.5 |
Other Income / Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Other Income / Expense | -0.6 | -1.8 | -0.9 | -0.9 | -0.8 |
Income Before Income Taxes | -9.7 | -9.4 | -9.0 | -7.6 | -7.3 |
Income Taxes | -1.2 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -8.5 | -9.4 | -9.0 | -7.6 | -7.3 |
Consolidated Net Income / Loss | -8.5 | -9.4 | -9.0 | -7.6 | -7.3 |
Net Income Attributable to Common Shareholders | -8.5 | -9.4 | -9.0 | -7.6 | -7.3 |
Basic EPS | -$0.21 | -$0.21 | -$0.19 | -$0.14 | -$0.13 |
Diluted EPS | -$0.21 | -$0.21 | -$0.19 | -$0.14 | -$0.13 |
Basic Shares Outstanding | 40.5M | 45.9M | 46.9M | 52.2M | 55.5M |
Diluted Shares Outstanding | 40.5M | 45.9M | 46.9M | 52.2M | 55.5M |